New Three-Drug cocktail aims to tame relapsed myeloma

NCT ID NCT04094961

Ongoing Disease control Sponsor: Omar Nadeem, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of three oral drugs—ixazomib, pomalidomide, and dexamethasone—given twice weekly to people whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to find a safe and effective dose that controls the cancer. The trial enrolls 52 participants and is currently active but no longer recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ixazomib (Ninlaro), Pomalidomide (Pomalyst), and Dexamethasone
What this could lead to: If successful, this could offer a new, more convenient oral combination to control multiple myeloma that has returned or stopped responding to other treatments.
What could go wrong: This is an early-phase trial with only 52 participants, so results may not apply to all patients. Side effects from the drug combination could be significant, and the regimen may not prove more effective than existing options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA MULTIPLE MYELOMA IN RELAPSE

Contacts and locations

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.